---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-294159"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2021-10-07T23:59:59+00:00"
generated_at: "2026-06-28T22:20:54.181069+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ORIC presents Phase 1b data on ORIC-101 in prostate cancer and preclinical data on ORIC-114

## Summary
- ORIC-101 (240 mg) + enzalutamide well tolerated at RP2D; adverse events mostly Grade 1-2, consistent with enzalutamide alone.
- No drug-drug interaction; plasma concentrations inhibited GR target; 76% of tumors had moderate-to-high GR expression.
- In patients lacking AR resistance markers (n=8), those with moderate/high GR (n=6) had prolonged time on treatment vs low GR (n=2).
- ORIC-114 showed superior brain penetration and tumor regressions in HER2+ breast cancer models; 90% CR in EGFR exon20 NSCLC xenograft.

## SEC filing metadata
- accession: 0001193125-21-294159
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2021-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312521294159/0001193125-21-294159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312521294159/d181647d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-294159
- JSON: https://secwatch.observer/filing/0001193125-21-294159.json
- Plain text: https://secwatch.observer/filing/0001193125-21-294159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.